The developments at Holland Capital in 2024 reflect our strong ambitions
Amsterdam/ Düsseldorf, 30th of December 2024 –The developments at Holland Capital in 2024 reflect our strong ambitions. Guided by a focused investment strategy, we continued to actively engage in the high-growth markets of Technology, Healthcare, and Agrifood. Reflecting on a successful year, we completed several key transactions and further strengthened our team.
2024 achievements
- The launch of our fund, Holland Capital Growth and Buy-Out Fund V
- Number of deals in the Netherlands: 5
- Number of add-on acquisitions in the Netherlands: 13
- Number of add-on acquisitions in Germany: 2
- Number of exits: 2
- Number of new colleagues: 4
Sector focus and an entrepreneurial hands-on approach: With specialized sector teams, we focus on the sectors of Healthcare, Technology, and Agrifood, both within the Growth & Buy-out and Venture & Growth segments. We understand the dynamics and opportunities in these sectors and have an extensive network. Holland Capital is not a passive investor; we work closely with management to define and execute strategies. Where needed, our operational team also contributes hands-on to the realization of specific projects within the company.
Which companies would we like to connect with?
- Sector: Technology, Healthcare, and Agrifood
- Positive outlook: Significant growth potential, both autonomous and buy-and-build
- Growth & Buy-out:
- Healthy profitability: cash flow from operations (EBITDA) between EUR 1 – 10m
- Smaller companies: considered as add-on acquisitions for our existing portfolio companies
- Larger companies: considered together with a co-investor
- Venture & Growth:
- Start-ups and scale-ups: EBITDA EUR <1m
- Cash flow negative (in an accelerated growth scenario)
- Revenue EUR 0 – 5m
What to expect from us?
- Flexible approach to transaction structures: We strive to adapt each structure to the needs of the company and its shareholders. Depending on the type of investment, Holland Capital either provides growth capital and/or acquires existing shares. We are flexible regarding the final capital structure: both majority and minority stakes are possible.
- Deal certainty and an efficient process: Thanks to our sector expertise, we are able to quickly assess a business model and put a fair price on the table. Since the partnership with the entrepreneur and/or the management team is the cornerstone of our investment, we devote above-average attention to ensuring the process is completed efficiently, in the right spirit, and with mutual respect for both parties.
- Transparency towards advisors: We appreciate it when advisors involve us early in discussions with entrepreneurs and/or management teams. In such cases, we always ensure that the advisor’s interests are well safeguarded throughout the process. The advisor retains the flexibility to decide whether to represent the sell-side or buy-side in a potential transaction.
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and Agrifood-Tech sector.
Quantib presents revolutionary software for dementia and MS diagnosis support and tracking
Rotterdam, The Netherlands – August 1st 2018. Quantib, market leader in artificial intelligence tools for radiology, released a major upgrade of their dementia and MS diagnosis support software Quantib™ ND. A substantial list of new features supporting the diagnosis...
Quantib presenteert revolutionaire software voor ondersteuning en tracking van dementie en MS-diagnose
Rotterdam, Nederland, 1 augustus 2018 - Quantib, marktleider in hulpmiddelen voor kunstmatige intelligentie voor radiologie, heeft een belangrijke upgrade van hun dementie en MS-diagnose-ondersteuningssoftware Quantib ™ ND uitgebracht. Een substantiële lijst met...
MedAngel takes away doubts about the effectiveness of medication
Digital healthcare startup receives investment from Holland Venture and Oost NLApeldoorn/Amsterdam, 13th of July 2018 – Uncertainties regarding the effectiveness of injectable medications is a major concern for millions of patients. There are many factors that can...
MedAngel neemt twijfels over werkzaamheid medicatie weg
Digitale healthcare start-up ontvangt investering van Holland Venture en Oost NL Apeldoorn/Amsterdam, 13 juli 2018 - Onzekerheid over de werking van je medicijnen, geen controle hebben over hoe je dag loopt, het houdt veel chronisch zieke patiënten bezig. Er zijn...
Avensus Group expands its security activitities by acquiring auditconnect
Amsterdam, 6th of July 2018 – Avensus Group acquires AuditConnect at the beginning of July 2018. The company focusses, with audit- and consultancy-activities, on improving the security- and IT-processes at large and medium-sized companies. The acquisition fits...
Avensus groep zet volgende stap in buy-and-build strategie met overname auditconnect
Amsterdam, 6 juli 2018 – Avensus Groep neemt vanaf begin juli 2018 AuditConnect over. De onderneming richt zich met audit- en consultancy-activiteiten op het verbeteren van de security- en IT-processen bij grote en middelgrote organisaties. Deze overname past...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl